Molecular targeted contrast-enhanced ultrasound (CEUS) imaging is a potential imaging strategy to improve the diagnostic accuracy of conventional ultrasound (US) imaging. US contrast agents are usually micrometer-sized and non-target gas bubbles while nano-sized and targeted agents containing phase-shift materials absorb more attractions for their size and the liquid core and excellent molecular imaging effect.
METHODS:
PLGA12k-mPEG2k-NH2, DSPE-mPEG2k and perfluorohexan (PFH) were used to construct a new targeted ultrasound contrast agent with CUB domain-containing protein 1 (CDCP1) receptor for the detection and diagnosis of prostate cancer. The potential of tumor-targeted nanoparticles (CDCP1-targeted perfluorohexan-loaded phase-transitional nanoparticles, anti-CDCP1 NPs) as contrast agents for ultrasound (US) imaging was assessed in vitro. Moreover, studies on the cytotoxicity and the targeting ability of anti-CDCP1 NPs assisted by US were carried out.
RESULTS:
The results showed that anti-CDCP1 NPs had low cytotoxicity, and with the increasing of polymer concentration in anti-CDCP1 NPs, the CEUS imaging of agent gradually enhanced, and enhanced imaging associated with the length of observing time. Furthermore, it was testified that anti-CDCP1 assisted the agent to target cells expressing CDCP1, which demonstrated the active targeting of anti-CDCP1 NPs in vitro.
CONCLUSION:
All in all, the feasibility of using targeted anti-CDCP1 NPs to enhance ultrasound imaging has been demonstrated in vitro, which laid a solid foundation for molecular US imaging in vivo, and anti-CDCP1 NPs might have a great clinical application prospect.
PostemaM, GiljaO. Contrast-enhanced and targeted ultrasound. World Journal of Gastroenterology. 2011;17(1):28–41.
2.
ShimC, LindnerJ. Cardiovascular molecular imaging with contrast ultrasound: principles and applications. Korean Circulation Journal. 2014;44(1):1–9.
3.
YangF, ChenZ, LinY. Advancement of targeted ultrasound contrast agents and their applications in molecular imaging and targeted therapy. Current Pharmaceutical Design. 2013;19(8):1516–27.
4.
ChenZ, WangY, LinY, ZhangJ, YangF, ZhouQ, LiaoY. Advance of molecular imaging technology and targeted imaging agent in imaging and therapy. BioMed Research International. 2014;2014:819324.
5.
OeffingerB, WheatleyM. Development and characterization of a nano-scale contrast agent. Ultrasonics. 2004;42:343–7.
6.
PereraR, HernandezC, ZhouH, KotaP, BurkeA, ExnerA. Ultrasound imaging beyond the vasculature with new generation contrast agents. Wiley interdisciplinary reviews. Nanomedicine and Nanobiotechnology. 2015;7(4):593–608.
7.
AndrewsL, ChanM, LiuR. Nano-lipospheres as acoustically active ultrasound contrast agents: evolving tumor imaging and therapy technique. Nanotechnology. 2019;30(18):182001.
8.
WangY, LiX, ZhouY, HuangP, XuY. Preparation of nanobubbles for ultrasound imaging and intracelluar drug delivery. International Journal of Pharmaceutics. 2010;384:148–53.
9.
WellerG, WongM, ModzelewskiR, LuE, KlibanovA, WagnerW, VillanuevaF. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. Cancer Research. 2005;65(2):533–9.
10.
StiegerS, DaytonP, BordenM, CaskeyC, GriffeyS, WisnerE, FerraraK. Imaging of angiogenesis using Cadence contrast pulse sequencing and targeted contrast agents. Contrast Media & Molecular Imaging. 2008;3(1):9–18.
VezeridisA, de Gracia LuxC, BarnhillS, KimS, WuZ, JinS, LuxJ, GianneschiN, MattreyR. Fluorous-phase iron oxide nanoparticles as enhancers of acoustic droplet vaporization of perfluorocarbons with supra-physiologic boiling point. Journal of Controlled Release: Official Journal of the Controlled Release Society. 2019;302:54–62.
WilsonK, HomanK, EmelianovS. Biomedical photoacoustics beyond thermal expansion using triggered nanodroplet vaporization for contrast-enhanced imaging. Nature Communications. 2012;3:618.
15.
LiJ, JiH, JingY, WangS. pH- and acoustic-responsive platforms based on perfluoropentane-loaded protein nanoparticles for ovarian tumor-targeted ultrasound imaging and therapy. Nanoscale Research Letters. 2020;15(1):31.
16.
WangY, SuiG, TengD, WangQ, QuJ, ZhuL, RanH, WangZ, JinC, WangH. Low intensity focused ultrasound (LIFU) triggered drug release from cetuximab-conjugated phase-changeable nanoparticles for precision theranostics against anaplastic thyroid carcinoma. Biomaterials Science. 2018;7(1):196–210.
SwamiU, McFarlandT, NussenzveigR, AgarwalN. Advanced Prostate Cancer: Treatment Advances and Future Directions. Trends in Cancer. 2020;6(8):702–15.
19.
GeR, WangZ, MontironiR, JiangZ, ChengM, SantoniM, HuangK, MassariF, LuX, CimadamoreA, Lopez-BeltranA, ChengL. Epigenetic modulations and lineage plasticity in advanced prostate cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2020;31(4):470–9.
20.
PeracaulaR, BarrabesS, SarratsA, RuddP, de LlorensR. Altered glycosylation in tumours focused to cancer diagnosis. Disease Markers. 2008;25:207–18.
21.
KollmorgenG, NiederfellnerG, LifkeA, SpohnG, RiederN, HarringS, BaussF, BurtscherH, LammersR, BossenmaierB. Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy. Molecular oncology. 2013;7(6):1142–51.
22.
AlajatiA, D’AmbrosioM, TroianiM, MosoleS, PellegriniL, ChenJ, RevandkarA, BolisM, TheurillatJ, GucciniI, LosaM, CalcinottoA, De BernardisG, PasquiniE, D’AntuonoR, SharpA, FigueiredoI, Nava RodriguesD, WeltiJ, GilV, YuanW, VlajnicT, BubendorfL, ChiorinoG, GnettiL, TorranoV, CarracedoA, CampleseL, HirabayashiS, CanatoE, Pasut, MontopoliM, RüschoffJ, WildP, MochH, De BonoJ, AlimontiA. CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. The Journal of clinical investigation. 2020;130(5):2435–50.
23.
CasarB, HeY, IconomouM, HooperJ, QuigleyJ, DeryuginaE. Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells. Oncogene. 2012;31(35):3924–38.
24.
BühringH, KuciS, ConzeT, RathkeG, BartolovićK, GrünebachF, Scherl-MostageerM, BrümmendorfT, SchweiferN, LammersR. CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin. Stem Cells (Dayton, Ohio). 2004;22(3):334–43.
25.
SivaA, WildM, KirklandR, NolanM, LinB, MaruyamaT, Yantiri-WernimontF, FredericksonS, BowdishK, XinH. Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model. Cancer Research. 2008;68(10):3759–66.
26.
DeryuginaE, ConnE, WortmannA, PartridgeJ, KupriyanovaT, ArdiV, HooperJ, QuigleyJ. Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination. Molecular Cancer Research: MCR. 2009;7(8):1197–211.
27.
Scherl-MostageerM, SommergruberW, AbseherR, HauptmannR, AmbrosP, SchweiferN. Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene. 2001;20(32):4402–8.
28.
IkedaJ, MoriiE, KimuraH, TomitaY, TakakuwaT, HasegawaJ, KimY, MiyoshiY, NoguchiS, NishidaT, AozasaK. Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells. The Journal of Pathology. 2006;210(1):75–84.
29.
WortmannA, HeY, DeryuginaE, QuigleyJ, HooperJ. The cell surface glycoprotein CDCP1 in cancer–insights, opportunities, and challenges. IUBMB Life. 2009;61(7):723–30.
30.
AwakuraY, NakamuraE, TakahashiT, KotaniH, MikamiY, KadowakiT, MyoumotoA, AkiyamaH, ItoN, KamotoT, ManabeT, NobumasaH, TsujimotoG, OgawaO. Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. Journal of Cancer Research and Clinical Oncology. 2008;134(12):1363–9.
31.
ZhaoY, SongW, WangD, RanH, WangR, YaoY, WangZ, ZhengY, LiP. Phase-Shifted PFH@PLGA/Fe3O4 Nanocapsules for MRI/US Imaging and Photothermal Therapy with near-Infrared Irradiation. ACS Applied Materials & Interfaces. 2015;7(26):14231–42.
32.
LiX, QinF, YangL, MoL, LiL, HouL. Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma. International Journal of Nanomedicine. 2014;9:3971–85.
33.
Hafezi GhahestaniZ, Alebooye LangroodiF, MokhtarzadehA, RamezaniM, HashemiM. Evaluation of anti-cancer activity of PLGA nanoparticles containing crocetin. Artificial Cells, Nanomedicine, and Biotechnology. 2017;45(5):955–60.
34.
PatelJ, AmrutiyaJ, BhattP, JaviaA, JainM, MisraA. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. Journal of Microencapsulation. 2018;35(2):204–17.
35.
BellettiD, RivaG, LuppiM, TosiG, ForniF, Vandelli M RuoziB, PederzoliF. Anticancer drug-loaded quantum dots engineered polymeric nanoparticles: Diagnosis/therapy combined approach. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences. 2017;107:230–9.
36.
FuH, MiaoC, RuiY, HuF, ShenM, XuH, ZhangC, DongY, WangW, GuH, DuanY. Strategy to prevent cardiac toxicity induced by polyacrylic acid decorated iron MRI contrast agent and investigation of its mechanism. Biomaterials. 2019;222:119442.
